Short Interest in GeoVax Labs Inc. (NASDAQ:GOVX) Drops By 51.5%

GeoVax Labs Inc. (NASDAQ:GOVX) was the recipient of a significant decline in short interest during the month of December. As of December 31st, there was short interest totaling 1,514,630 shares, a decline of 51.5% from the December 15th total of 3,124,146 shares. Based on an average trading volume of 6,248,406 shares, the short-interest ratio is presently 0.2 days. Approximately 5.1% of the shares of the company are sold short. Approximately 5.1% of the shares of the company are sold short. Based on an average trading volume of 6,248,406 shares, the short-interest ratio is presently 0.2 days.

Analysts Set New Price Targets

A number of analysts have recently commented on GOVX shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of GeoVax Labs in a research report on Wednesday, October 8th. D. Boral Capital reduced their price objective on GeoVax Labs from $225.00 to $150.00 and set a “buy” rating for the company in a research note on Wednesday, November 19th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $187.50.

GeoVax Labs Stock Performance

GeoVax Labs stock traded up $0.08 during trading hours on Thursday, reaching $2.94. 267,853 shares of the stock were exchanged, compared to its average volume of 207,903. The stock has a market cap of $3.53 million, a P/E ratio of -0.08 and a beta of 3.67. GeoVax Labs has a 52-week low of $2.61 and a 52-week high of $57.50. The firm’s 50 day moving average is $7.88 and its 200 day moving average is $13.52.

GeoVax Labs (NASDAQ:GOVX) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($7.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($6.00) by ($1.75). GeoVax Labs had a negative return on equity of 489.67% and a negative net margin of 403.88%. Equities research analysts expect that GeoVax Labs will post -4.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Jane Street Group LLC acquired a new stake in GeoVax Labs in the first quarter valued at $27,000. Hudson Bay Capital Management LP acquired a new stake in shares of GeoVax Labs in the third quarter valued at about $47,000. Armistice Capital LLC purchased a new stake in GeoVax Labs during the third quarter worth about $253,000. Finally, Sabby Management LLC acquired a new stake in shares of GeoVax Labs during the 3rd quarter valued at approximately $313,000. Institutional investors and hedge funds own 6.09% of the company’s stock.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.